Look beyond investment styles to find true value

A professional investor tells us where he’d put his money. This week: Tom Wildgoose of the Nomura Global High Conviction Fund highlights three favourites

A recurring theme in financial markets is the division between “growth” and “value”, two key styles of investing that are always pitted against each other. In recent years the growth style has outperformed value. Value funds have shrunk in size, while growth funds have topped the performance charts.

However, there is more to this story than the two styles, and the crucial point is that the type of investing deemed value has come to be defined in an overly rigid and ultimately unhelpful way. We consider ourselves value investors and we have managed to outperform while the value style has underperformed.

How it all began 

The explanation starts with the capital asset pricing model (CAPM), which was introduced in the 1960s to explain the expected, or required, return of a stock using the anticipated market return, the stock’s beta (relative volatility) and the risk-free rate (typically defined as the inflation-adjusted bond yield matching the duration of the investment in question).

Then in the 1990s, renowned academics Eugene Fama and Kenneth French added two “factors” to the CAPM to create the Fama-French three-factor model: these were market capitalisation (known as the “size factor”) and price-to-book value (known as the “value factor”). 

Further developments have added others, such as the recently successful “growth factor”. Growth and value have thus come to be seen as both distinct and mutually exclusive, which is a problem for genuine value investors who may find themselves pigeonholed as having a value style when they don’t. 

Value investors do not necessarily have a style – they just buy stocks when the current price is below their estimate of its intrinsic value (doesn’t everyone do this, you might wonder?). In contrast, the value factor advises buying any (and every) stock that has a low price compared to book value. While these are not entirely different concepts the gap between them is wide and explains the disparity of investment results among value investors, even as the value style has consistently underperformed in recent years. 

Where to look now 

Take Humana (NYSE: HUM), a US health insurer focused on older people. It has a reasonably strong exposure to the value factor, but it has risen significantly since we bought the stock, despite the overall underperformance of value. The next few months might be affected by the ebbs and flows of the US presidential election, but the longer-term outlook is attractive given the likely growth in the size of their target market as the population ages.

In contrast, Network International (LSE: NETW), a Middle Eastern payment processor with a very strong market position, is apparently underexposed to value. We are not worried about that, though, as our projections for future cash flow tell us that the stock price is below a conservative estimate of its intrinsic value.

Another value stock is Comcast (Nasdaq: CMCSA), the cable and satellite TV network owner and broadcaster. We think its broadband subscriber growth and profit margin trends point to a positive contribution to our investment performance in the future even if the value style continues to underperform. 

Recommended

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
What's behind Sri Lanka’s crippling debt crisis?
Emerging markets

What's behind Sri Lanka’s crippling debt crisis?

Sri Lanka has been hit by a triple whammy of economic shocks and has gone to the IMF for a bailout. It may just be the first domino to fall in a globa…
20 May 2022
Investing in drugmakers: uncommon profits from curing rare diseases
Share tips

Investing in drugmakers: uncommon profits from curing rare diseases

Treatments for medical conditions with only a small number of sufferers can still be very attractive for pharmaceutical companies and investors becaus…
20 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022

Most Popular

Barry Norris: we’re already in the 1970s. Here’s how to invest
Investment strategy

Barry Norris: we’re already in the 1970s. Here’s how to invest

Merryn talks to Barry Norris of Argonaut capital about the parallels between now and the 1970s; the transition to “green” energy; and the one sector w…
19 May 2022
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves looks at the FTSE 100’s top yielding stocks for income investors to consider.
18 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022